Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 20;8(2):e000772. doi: 10.1136/jitc-2020-000772

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

DC vaccination-αCD40 combination therapy improves survival of tumor-bearing mice. (A) Subcutaneous tumor model study setup. Mice were treated with AE17-lysate DCs and FGK45. (B) Tumor volumes measured over time. (C) Tumor size at day 21. (D) Kaplan-Meier analysis of treated and untreated animals. (E) Tumor volumes measured over time. (F) Tumor size at day 22. (G) Kaplan-Meier analysis of treated and untreated animals. (H) Orthotopic tumor model study setup. (I) Percentage of tumor bearing mice. (J) Tumor weight on day 17. n=8–10 per group. Significance was determined using the non-parametric Mann-Whitney U test or log-rank test. Data presented as the mean±SEM. *P<0.05, **P<0.01, ***P<0.001. DC, dendritic cell.